More than $582 Billion in New U.S. Investment Since 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
The world’s pharmaceutical companies are stepping up their investments in America.
We Work For Health’s tracking tool, the U.S. Biopharma Investment Watch, is documenting these developments and providing visibility into the sector's robust expansion and critical role in securing America's position as the global leader in health care innovation. Since January 2025, companies have committed to investing more than $582 billion to bolster U.S. research and development, expand manufacturing, and create jobs across the country.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,488%
increase in announced U.S. facility investments in 2025 vs 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Sep 23, 2025
Eli Lilly
$6.5 billion
Houston-TX
New next-generation API manufacturing facility that will focus on small molecule medicines across several therapeutic areas, including cardiometabolic health, immunology, neuroscience and oncology. Scheduled to be operational within five years, the facility will create 615 permanent high-wage jobs plus 4,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
Sep 17, 2025
GSK
$30 billion
PA, NC, MD, MT
A five-year commitment to upgrade research and development and supply chain infrastructure. Includes a $1.2 billion investment in advanced U.S. manufacturing and digital capabilities, including a new biologics flex factory in Upper Merion, Pa., to produce next-generation respiratory and cancer medicines.
The investment will also bring AI and advanced digital technologies to GSK’s five existing sites in Pennsylvania, North Carolina, Maryland, and Montana, along with expanded drug substance, device, and auto-injector capabilities.
Sep 16, 2025
Eli Lilly
$5 billion
Goochland County-VA
The first dedicated, fully integrated API and drug product facility for Lilly's emerging bioconjugate platform and monoclonal antibody portfolio. About 1,800 construction jobs and more than 650 new high-paying jobs, including engineers, scientists and lab technicians, will be brought to the Richmond, Virginia region.
Part of a larger, previously announced $27 billion company investment.
Sep 3, 2025
Gilead
Unspecified
Foster City-CA
A new facility that will enhance technical development and manufacturing through advanced automation, robotics, and digital monitoring. The project also expands the company’s focus on biologics.
Part of a $4 billion commitment in 2025 to U.S. capital projects.
Jul 21, 2025
AstraZeneca
$50 billion
MD, CA, TX, VA, IN
Pledge focus is a new drug substance manufacturing campus in Virginia and expansions of R&D and cell therapy manufacturing elsewhere.
AstraZeneca will also upgrade its U.S. clinical trial supply network and accelerate development of novel medicines.
Total investment is expected to add tens of thousands of U.S. jobs.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page